In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4.
By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients. Immunotherapy , especially immune checkpoint blockade (ICB), has transformed cancer treatment. However, many patients develop resistance to current treatments like anti-PD-1 and anti-CTLA-4.
This resistance underscores the need for ongoing research to discover new immune checkpoint targets and enhance treatment efficacy . Based on these challenges, it is crucial to conduct in-depth studies to identify additional immune checkpoint inhibitors (ICIs) and develop combination therapies that can provide more effective cancer treatments. Researchers from Guangdong Pharmaceutical University published a comprehensive review (DOI:10.
20892/j.issn.2095-3941.
2024.0055) in Cancer Biology & Medicine on May 24th, 2024, highlighting recent progress in ICIs. The study, led by Xueqing Kong and colleagues, discusses novel .